Elizabeth Mittendorf, M.D., Ph.D.

Dr. Mittendorf is the Rob and Karen Hale Distinguished Chair in Surgical Oncology at the Brigham and Women’s Hospital. She is the Director of Research in Breast Surgery as well as the Director of the Breast Immuno-Oncology program at the Dana-Farber/Brigham and Women’s Cancer Center. Dr. Mittendorf has focused both her clinical and laboratory efforts on the study of breast cancer, specifically on breast cancer immunotherapy. She has been the Principal Investigator of several breast cancer vaccine trials including the Phase III PRESENT clinical trial and a multicenter Phase II trial that investigates the efficacy of two additional HER2-derived peptide vaccines. Dr. Mittendorf also serves as the principal investigator on two investigator-initiated pre-surgical studies evaluating immune checkpoint blockade agents in breast cancer patients.  The current focus of her laboratory work is to determine the impact of standard and experimental therapies on immunologic aspects of the tumor microenvironment in order to inform rational trials of immunotherapeutic agents in breast cancer and novel targets for vaccine strategies.

Dr. Mittendorf serves as the CITO’s Senior Cancer Clinical Translation Investigator, an Administrative Core Co-Leader, and Co-Leader of Project 1 with Dr. Haifa Shen and Dr. Rongfu Wang.